Europe CIS
Europe CIS provides a broad range of Sterile Focus and Regional Brands and undertakes third-party manufacturing. The revenue contribution from the Sterile Focus Brands portfolio is the second highest after Asia, and consists of Anaesthetics and to a lesser extent Thrombosis products in Russia and the Europe CIS region. The manufacturing operations, which span across both active pharmaceutical ingredients (“APIs”) and FDF production, are widely accredited and provide a variety of technologies for Aspen’s own commercialisation strategy and for third-party use.
Key Countries
France
Germany
Ireland
Netherlands
Russian Federation
KEY BRANDS
Brand | Therapeutic category | |
Emla | Local anaesthetic | |
Fraxiparine | Low molecular weight heparin | |
Ovestin | Estrogen hormone replacement | |
Ultiva | Injectable general anaesthetic | |
Xylocaine | Regional anaesthetic |
NUMBER OF PERMANENT EMPLOYEES
2 192
June 2022
2 195
June 2021

STATISTICS
Number of products launched:
Nil
(2021: 1)
Number of product recalls:
5
(2021: 2)
Average staff turnover:
9%
(2020: 11%)
Number of work-related fatalities:
Nil
(2021: Nil)
Sales representatives:
140
(2021: 149)
Revenue | 2021 R’million |
2020 (CER) R’million |
Change % |
||||
---|---|---|---|---|---|---|---|
Commercial Pharmaceuticals | 4 737 | 4 931 | (4) | ||||
Regional Brands | 1 594 | 1 582 | 1 | ||||
Sterile Focus Brands | 3 143 | 3 349 | (6) | ||||
Manufacturing | 8 368 | 7 783 | 8 | ||||
FDF | 3 175 | 2 104 | 51 | ||||
API Biochem | 778 | 1 161 | (33) | ||||
API Chemicals | 4 415 | 4 518 | (2) | ||||
Total | 13 105 | 12 714 | 3 |
Note: Commercial Pharmaceuticals revenue is by customer geography and Manufacturing revenue is by place of manufacture.